170367-68-7

Basic information

• Product Name: Carbamic acid, [(1R)-2-cyano-1-methylethyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [(1R)-2-cyano-1-methylethyl]-, 1,1-dimethylethyl ester (9CI);tert-butyl [(1R)-2-cyano-1-Methylethyl]carbaMate;tert-butyl (R)-(1-cyanopropan-2-yl) carbamate;(R)-tert-Butyl (1-cyanopropan-2-yl)carbamate
• CAS NO: 170367-68-7
• Molecular Formula: C₉H₁₆N₂O₂
• Molecular Weight: 184.23554
• Product Categories: N-BOC
• Mol File: 170367-68-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Carbamic acid, [(1R)-2-cyano-1-methylethyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1R)-2-cyano-1-methylethyl]-, 1,1-dimethylethyl ester (9CI)(170367-68-7)
• EPA Substance Registry System: Carbamic acid, [(1R)-2-cyano-1-methylethyl]-, 1,1-dimethylethyl ester (9CI)(170367-68-7)

Safety Data

• Hazardous Substances Data: 170367-68-7(Hazardous Substances Data)

Usage

Description

Carbamic acid, [(1R)-2-cyano-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) is an organic compound with a complex chemical structure, characterized by its carbamic acid core and various functional groups. It is a derivative of carbamic acid, featuring a 2-cyano-1-methylethyl group and a 1,1-dimethylethyl ester group. Carbamic acid, [(1R)-2-cyano-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) is known for its potential applications in the pharmaceutical and chemical industries due to its unique properties and reactivity.

Uses

Used in Pharmaceutical Industry:
Carbamic acid, [(1R)-2-cyano-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) is used as an intermediate in the synthesis of various biologically active compounds. Its unique structure allows it to be a key component in the development of new drugs with specific therapeutic properties.
Used in Synthesis of Immunosuppressive Agents:
Carbamic acid, [(1R)-2-cyano-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) is used as an intermediate for the synthesis of spermidine analogs of 15-deoxyspergualin, which possess immunosuppressive activities. These analogs can be employed in the treatment of autoimmune diseases and transplantation medicine to prevent organ rejection.
Used in Synthesis of HIV-1 Inhibitors:
Carbamic acid, [(1R)-2-cyano-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) is also utilized in the preparation of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists. These antagonists serve as inhibitors of M-tropic (R5) HIV-1 replication, playing a crucial role in the development of antiretroviral drugs for the treatment of HIV/AIDS.

Upstream product

• 194156-55-3 tert-butyl 1-cyanopropan-2-ylcarbamate 
• 773837-37-9 sodium cyanide 
• 352705-03-4 (2R)-2-[(tert-butoxycarbonyl)amino]propyl 4-methylbenzene-1-sulfonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 126301-16-4 (2R)-2-[(tert-butoxycarbonyl)amino]propyl methanesulfonate 
• 79069-13-9 (R)-2-tertbutoxycarbonylamino-1-propanol 
• 143-33-9 sodium cyanide 

Downstream Products

• 170367-70-1 [1(R)-methyl-3-[(phenylmethyl)amino]propyl]carbamic acid, 1,1-dimethylethyl ester 
• 170367-71-2 3-[(3-cyanopropyl)(phenylmethyl)amino-1(R)-methylpropyl]carbamic acid, 1,1-dimethylethyl ester 
• 170367-72-3 3-[(4-aminobutyl)(phenylmethyl)amino-1(R)-methylpropyl]carbamic acid, 1,1-dimethylethyl ester 
• 252353-69-8 [3-[[4-(2,4-dioxo-3-oxazolidinyl)butyl](phynylmethyl)amino]-1-methylpropyl]carbamic acid, 1,1-dimethylethyl ester (R) 
• 170367-76-7 2,2,6-trimethyl-4,15-dioxo-9-(phenylmethyl)-3,16-dioxa-5,9,14-triazaoxadecan-18-oic acid (R) 
• 170367-82-5 [21-[[(1,1-dimethylethoxy)carbonyl]amino]-1,25,25-trimethyl-10,12,23-trioxo-4-(phenylmethyl)-24-oxa-4,9,13,20,22-pentaaza-21-hexacosen-1-yl]carbamic acid, 1,1-dimethylethyl ester (R) 
• 170367-78-9 [4-[[3-[[(1,1-dimethylethoxy)carbonyl]amino]butyl](phenylmethyl)amino]butyl]carbamic acid, 11-[[(1,1-dimethylethoxy)carbonyl]amino]-15,15-dimethyl-2,13-dioxo-14-oxa-3,4,12-triaza-11-hexadecen-1-yl ester (R) 
• 6078-06-4 (R)-methyl 3-aminobutanoate hydrochloride 
• 159991-23-8 (R)-3-((tert-butoxycarbonyl)amino)butanoic acid 
• 932032-31-0 (R)-N¹²-(tert-butyloxycarbonyl)-N⁹-(o-nitrophenylsulfonyl)-1,12-diamino-4,9-diazatridecane 
• 932032-30-9 (R)-N⁵-(o-nitrophenylsulfonyl)-N⁸-(tert-butyloxycarbonyl)-8-amino-5-aza-1-iodononane 
• 875680-91-4 (R)-N¹-phthaloyl-N⁵-(o-nitrophenylsulfonyl)-N⁸-(tert-butyloxycarbonyl)-1,8-diamino-5-azanonane 
• 875680-89-0 (R)-N¹-(o-nitrophenylsulfonyl)-N³-(tert-butyloxycarbonyl)-1,3-diaminobutane 
• 170367-69-8 (3-amino-1(R)-methylpropyl)carbamic acid, 1,1-dimethylethyl ester 

Relevant articles and documents

Process Optimisation Studies and Aminonitrile Substrate Evaluation of Rhodococcus erythropolis SET1, A Nitrile Hydrolyzing Bacterium

A comprehensive series of optimization studies including pH, solvent and temperature were completed on the nitrile hydrolyzing Rhodococcus erythropolis bacterium SET1 with the substrate 3-hydroxybutyronitrile. These identified temperature of 25 °C and pH of 7 as the best conditions to retain enantioselectivity and activity. The effect of the addition of organic solvents to the biotransformation mixture was also determined. The results of the study suggested that SET1 is suitable for use in selected organo-aqueous media at specific ratios only. The functional group tolerance of the isolate with unprotected and protected β-aminonitriles, structural analogues of β-hydroxynitriles was also investigated with disappointingly poor isolated yields and selectivity obtained. The isolate was further evaluated with the α- aminonitrile phenylglycinonitrile generating acid in excellent yield and ee (>99 % (S) – isomer and 50 % yield). A series of pH studies with this substrate indicated pH 7 to be the optimum pH to avoid product and substrate degradation.

Practical convergent laboratory-scale synthesis of a CCR5 receptor antagonist

An efficient laboratory-scale synthesis has been developed for the selective CCR5 antagonist 1. The convergent route has a longest linear sequence of nine steps (15 steps overall), and has overall yields of 18-25%. The route has enabled the preparation of 550 g of 1.

3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE'S AND 3-SUBSTITUTED 1,3-PYRIMIDINONE'S FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson''s disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke- induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi''s syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.